Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02990078 · ClinicalTrials.gov registry record
Non-invasive Measurement of Cerebrovascular Reactivity After Traumatic Brain Injury
A clinical trial, sponsored by University of Pennsylvania.
- Terminated
- Registry status
- 26
- Enrollment target
NCT02990078: Clinical Trial study, sponsored by University of Pennsylvania.
NCT02990078 is a clinical trial that was terminated before completion, run by University of Pennsylvania. The registered enrollment target is 26 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02990078 was terminated before completion, sponsored by University of Pennsylvania.
- TERMINATED
- Registry status
- 26 participants
- Enrollment target
Study Summary
The investigators will longitudinally measure cerebrovascular reactivity (CVR) by functional near-infrared spectroscopy (fNIRS) in acute (≤3 days from injury), subacute, and chronic phases after TBI as a biomarker of TCVI as compared to healthy controls. CVR will be measured by fNIRS response to hypercapnia. The investigators hypothesize that CVR will be decreased after TBI and that these decreases will correlate with clinical outcomes. Furthermore, the investigators predict that administration of a vasodilatory medication (sildenafil) will augment CVR after TBI.
Interventions
- DRUG Sildenafil citrate
- DEVICE Functional Near Infared Spectroscopy
- OTHER Hypercapnia Challenge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2016-12 |
| Est. Completion | 2022-09-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02990078
The ClinicalTrials.gov registry entry for NCT02990078 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Sildenafil citrate is the first listed.
NCT02990078 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02990078 about?
NCT02990078 is a clinical study titled "Non-invasive Measurement of Cerebrovascular Reactivity After Traumatic Brain Injury". The investigators will longitudinally measure cerebrovascular reactivity (CVR) by functional near-infrared spectroscopy (fNIRS) in acute (≤3 days from injury), subacute, and chronic phases after TBI as a biomarker of TCVI as compared to healthy controls. CVR will be measured by fNIRS response to hyp...
What is the current status of trial NCT02990078?
This trial is currently terminated. The enrollment target is 26 participants. The study started on 2016-12. Estimated completion is 2022-09-30.
What interventions are being tested in trial NCT02990078?
The interventions under investigation include: Sildenafil citrate (DRUG), Functional Near Infared Spectroscopy (DEVICE), Hypercapnia Challenge (OTHER).
Who is sponsoring clinical trial NCT02990078?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.